Cirrhosis

There are 640 papers on cirrhosis in aging research: 56 trials and 343 observational studies in people, 43 in animals, 3 in cells, 170 reviews. The newest story, Nov 17, 2026: “Model infers biological roles of unidentified molecules”.

Disease

640 papers study it396 more mention it110 findings

68 new papers in 30 daysSee all 1,036 papers on cirrhosis

At a glance

Human studies link short telomeres, accelerated biological aging, and frailty with higher cirrhosis risk. Cirrhosis is also associated with sarcopenia, although a study of elderly hospitalized patients finds no clear link. One study in aging male mice reports lower cirrhosis risk with exercise.

110 findings in 89 papers from 2016 to 2026, 19 of them since April 2026

“liver cirrhosis (K74: HR = 4.73, 95% CI: 3.27-6.85)”
Association of leukocyte telomere length with the risk of digestive diseases: A large-scale cohort studyChinese medical journal2024doi:10.1097/cm9.0000000000002994
  • Human trial56
  • Humans343
  • Animals43
  • Cells3
  • In silico14

Interventions

5

Lanthanum carbonate

downin mice1

1 study
  1. Lanthanum carbonate protects against cirrhosis in CCl4-induced cirrhosis and HE murine models.

    “alleviating cirrhosis and HE and reversing liver dysfunction”

    Animalsin CCl4-induced cirrhosis and HE murine models

    Phosphate binders suppress glutaminase activity for treatment of cirrhosis and hepatic encephalopathy murine models

    Biochemical pharmacology

More on Lanthanum carbonate

Sevelamer

downin mice1

1 study
  1. Sevelamer protects against cirrhosis in CCl4-induced cirrhosis and HE murine models.

    “alleviating cirrhosis and HE and reversing liver dysfunction”

    Animalsin CCl4-induced cirrhosis and HE murine models

    Phosphate binders suppress glutaminase activity for treatment of cirrhosis and hepatic encephalopathy murine models

    Biochemical pharmacology

More on Sevelamer

Multivitamins

no changein humans1

1 study
  1. Multivitamins were not clearly linked with cirrhosis in individuals with MASLD.

    “No significant reduction was found for liver-related mortality or liver cirrhosis incidence.”

    Humansin individuals with MASLD7 years

    Multivitamin supplementation and its impact in metabolic dysfunction-associated steatotic liver disease

    Scientific reports

More on Multivitamins

Phlebotomy

downin humans1

1 study
  1. Phlebotomy prevents cirrhosis in humans (early diagnosis and treatment of hemochromatosis).

    “Early diagnosis and treatment by phlebotomy can prevent cirrhosis, hepatocellular carcinoma, diabetes, arthropathy and other complications.”

    Reviewearly diagnosis and treatment of hemochromatosisliver

    Recommendations of EASL clinical practice guidelines on haemochromatosis

    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

More on Phlebotomy

Caloric restriction

downin rats1

1 study
  1. Caloric restriction prevents cirrhosis in rats (diethylnitrosamine-induced cirrhosis-hepatocarcinoma model).

    “We conclude that time-caloric restriction prevents fibrosis from progressing into cirrhosis”

    Animalsdiethylnitrosamine-induced cirrhosis-hepatocarcinoma model18 weeks

    Time-caloric restriction inhibits the neoplastic transformation of cirrhotic liver in rats treated with diethylnitrosamine

    Carcinogenesis

More on Caloric restriction

Effects

10

Knee extension strength

downin humans1

1 study
  1. Cirrhosis impairs knee extension strength in humans (versus age-matched control) (SMD: 3.48, 95% CI 2.35-4.61, p<0.001).

    “Muscle strength was impaired in patients with cirrhosis versus age-matched control (standardized mean difference, SMD: 3.48, 95% CI 2.35-4.61, I2 = 96.5%, p<0.001)”

    Reviewversus age-matched control

    Knee extension strength in patients with liver cirrhosis and the impact of interventions: systematic review and meta-analysis

    Acta gastro-enterologica Belgica

Sarcopenia

no changein humans1

1 study
  1. Cirrhosis was not clearly linked with sarcopenia in humans (elderly hospitalized patients) (62% vs 63%).

    “probable sarcopenia prevalence was similar in cirrhotic (62%) and non-cirrhotic (63%) patients.”

    Humanselderly hospitalized patientsn = 115

    Comparative analysis of Sarcopenia in hospitalized elderly: exploring the impact of liver cirrhosis

    Internal and emergency medicine

More on Sarcopenia

Mortality

upin humans1

1 study
  1. Cirrhosis is linked with higher mortality in humans (isolated hip fractures) (12% vs 2%, P < .05).

    “cirrhosis/substance abuse demonstrated increased mortality.”

    Humansisolated hip fracturesn = 785

    Isolated Hip Fractures in the Elderly: Best Practice Analysis of Perioperative Medical Optimization Including Effect of Comorbidities, Functional Status, and Demographics

    The American surgeon

adipogenic differentiation

downin human cells1

1 study
  1. Cirrhosis decreases adipogenic differentiation in human cells (BMSCs from patients versus healthy volunteers) (slightly increased in BCs).

    “Adipogenic differentiation slightly increased in BCs”

    CellsBMSCs from patients versus healthy volunteersbone marrow-derived mesenchymal stem cellsn = 6

    Bone Marrow-Derived Mesenchymal Stem Cells Isolated from Patients with Cirrhosis and Healthy Volunteers Show Comparable Characteristics

    International journal of stem cells

Mitochondrial membrane potential

no changein human cells1

1 study
  1. Cirrhosis showed no clear effect on mitochondrial membrane potential in human cells (BMSCs from patients versus healthy volunteers).

    “mitochondrial membrane potential, oxygen consumption rate, and expression of mitochondria-related genes such as cytochrome c oxidase 1 were not significantly different between BCs and BPs”

    CellsBMSCs from patients versus healthy volunteersbone marrow-derived mesenchymal stem cellsn = 6

    Bone Marrow-Derived Mesenchymal Stem Cells Isolated from Patients with Cirrhosis and Healthy Volunteers Show Comparable Characteristics

    International journal of stem cells

More on Mitochondrial membrane potential

CD73, CD90 and CD105 expression

no changein human cells1

1 study
  1. Cirrhosis showed no clear effect on CD73, CD90 and CD105 expression in human cells (BMSCs from patients versus healthy volunteers).

    “No difference was observed in the expression of CD73, CD90, or CD105 between BCs and BPs.”

    CellsBMSCs from patients versus healthy volunteersbone marrow-derived mesenchymal stem cellsn = 6

    Bone Marrow-Derived Mesenchymal Stem Cells Isolated from Patients with Cirrhosis and Healthy Volunteers Show Comparable Characteristics

    International journal of stem cells

More on CD73, CD90 and CD105 expression

Cellular senescence

upin human cells1

1 study
  1. Cirrhosis increases cellular senescence in human cells (BMSCs from patients versus healthy volunteers, passage 3) (slightly higher).

    “In passage 3 (P3), senescent population and expression of p53 and p21 were slightly higher in BPs”

    CellsBMSCs from patients versus healthy volunteers, passage 3bone marrow-derived mesenchymal stem cellsn = 6

    Bone Marrow-Derived Mesenchymal Stem Cells Isolated from Patients with Cirrhosis and Healthy Volunteers Show Comparable Characteristics

    International journal of stem cells

More on Cellular senescence

Population doubling time

downin human cells1

1 study
  1. Cirrhosis decreases population doubling time in human cells (BMSCs from patients versus healthy volunteers, passages 3-5) (65.3±11.1 h vs 83.7±9.2 h; 18.4 h shorter).

    “the average population doubling time for P3-P5 in BPs was approximately 65.3±11.1 h, which is 18.4 h shorter than that in BCs (83.7±9.2 h)”

    CellsBMSCs from patients versus healthy volunteers, passages 3-5bone marrow-derived mesenchymal stem cellsn = 6

    Bone Marrow-Derived Mesenchymal Stem Cells Isolated from Patients with Cirrhosis and Healthy Volunteers Show Comparable Characteristics

    International journal of stem cells

Health-related quality of life

downin humans1

1 study
  1. Cirrhosis is linked with worse health-related quality of life in humans (compared to non-cirrhotics).

    “Cirrhotics were impaired on non-amnestic and selected amnestic tests, HRQOL and systemic inflammation compared to non-cirrhotics.”

    Humanscompared to non-cirrhotics

    Elderly patients have an altered gut-brain axis regardless of the presence of cirrhosis

    Scientific reports

Cognitive function

downin humans1

1 study
  1. Cirrhosis is linked with worse cognitive function in humans (compared to non-cirrhotics).

    “Cirrhotics were impaired on non-amnestic and selected amnestic tests, HRQOL and systemic inflammation compared to non-cirrhotics.”

    Humanscompared to non-cirrhotics

    Elderly patients have an altered gut-brain axis regardless of the presence of cirrhosis

    Scientific reports

Upstream

1

KDM biological age

mediatesin humans1

1 study
  1. KDM biological age is linked with cirrhosis in humans (association of NH4+ and SO42- with liver cirrhosis) (14.7 % and 14.6 %).

    “the mediated proportion of biological age on associations of NH4+ and SO42− with liver cirrhosis were 14.7 % and 14.6 %, respectively.”

    Humansassociation of NH4+ and SO42- with liver cirrhosis

    Accelerated biological aging mediated associations of ammonium, sulfate in fine particulate matter with liver cirrhosis

    The Science of the total environment

More on KDM biological age

Associations

71

Mortality

upin humans10HR 1.562–4.251

10 studies
  1. Cirrhosis is associated with mortality in humans (sepsis survivors) (HR 1.562).

    “Neoplasia (hazard ratio [HR], 2.011), liver cirrhosis (HR, 1.562), and dementia (HR, 1.304) were the comorbidities most strongly associated with mortality.”

    Humanssepsis survivorswithin 2 years after hospital discharge

    Sepsis survivors faced high mortality after hospital discharge

    Critical care medicine

  2. Cirrhosis is linked with a higher risk of mortality in patients with alcohol use disorder (HR 2.55, 95% CI 2.39-2.72).

    “Development of cirrhosis doubled the mortality rate (HR, 2.55; 95% CI, 2.39-2.72; p<0.001).”

    Humansin patients with alcohol use disorderaverage 5.7 yearsn = 32,808

    High incidence of advanced liver disease and mortality in patients presenting with alcohol use disorder

    Hepatology communications

  3. Cirrhosis is linked with a higher risk of mortality in humans (undergoing urgent or emergent laparotomy within 6-hours of arrival).

    “The strongest independent associated patient-related risk factor for death was cirrhosis (OR 8.28, CI 2.25-30.46, p = 0.001).”

    Humansundergoing urgent or emergent laparotomy within 6-hours of arrivaln = 701

    Evaluating predictors of mortality in octogenarians undergoing urgent or emergent trauma laparotomy

    European journal of trauma and emergency surgery : official publication of the European Trauma Society

  4. Cirrhosis is linked with a higher risk of mortality in humans (controlling for ISS category) (aOR 3.03 (mild), 3.63 (moderate), 3.46 (severe)).

    “Patients who had cirrhosis or congestive heart failure (CHF) were at increased odds of mortality after adjusting for mild (aOR: 3.03, 1.61), moderate (aOR: 3.63, 2.14), and severe (aOR: 3.46, 1.93) injuries, respectively.”

    Humanscontrolling for ISS category

    Morbidity and Mortality of Trauma Patients 55 and Older: A Study of Nontrauma Risk Factors

    The American surgeon

  5. Cirrhosis is associated with mortality in humans (Liver cirrhosis reported in medical history) (HR 4.251; p < 0.001).

    “liver cirrhosis (HR 4.251, p < 0.001)”

    HumansLiver cirrhosis reported in medical history

    Event dependent overall survival in the population-based LIFE-Adult-Study

    PloS one

  6. Cirrhosis is linked with a higher risk of mortality in humans (geriatric patients taking anticoagulants who sustained a ground level fall).

    “advanced age, male gender, high ISS, low GCS, presence of hypotension, CHF, CRF, COPD and cirrhosis were highly significant for odds of mortality.”

    Humansgeriatric patients taking anticoagulants who sustained a ground level falln = 10,368

    Early risk stratification of mortality in the geriatric patients who are at high risk for bleeding and fall from a ground level: an analysis of the national data

    Journal of injury & violence research

  7. Cirrhosis is associated with mortality in humans (severe hyponatremia) (p = 0.036).

    “Mortality was associated with chronic liver disease/cirrhosis (p = 0.036)”

    Humanssevere hyponatremia

    Risk factors and mortality in elderly patients with severe hyponatremia admitted to the emergency department

    Irish journal of medical science

  8. Cirrhosis predicts mortality in humans (upper gastrointestinal bleeding) (OR 2.88, 95% CI 1.88-17.34).

    “cirrhosis (OR: 2.88, 95% CI: 1.88-17.34; P = .04) and being an impatient (OR: 3.90; 95% CI: 1.11-20; P = .035) were independent risk factors for mortality in older patients.”

    Humansupper gastrointestinal bleeding

    Upper gastrointestinal bleeding in patients 80 years old and over. A comparison with younger patients and risk factors analysis for in-hospital and delayed mortality

    International journal of clinical practice

  9. Cirrhosis is linked with a higher risk of mortality in humans (HIV-1 infection) (aHR 2.99, 95% CI 1.68-5.33).

    “cirrhosis (aHR=2.99; 95%CI[1.68-5.33]; p<10-3)”

    HumansHIV-1 infection5 yearsn = 1,415

    Impact of Age-related Comorbidities on Five-year Overall Mortality among Elderly HIV-Infected Patients in the Late HAART Era--Role of Chronic Renal Disease

    The journal of nutrition, health & aging

  10. Cirrhosis raises the risk of mortality in humans (presence of cirrhosis or fibrosis) (HR = 3.22, 95% CI: 2.40-4.33).

    “The presence of cirrhosis or fibrosis further elevated the risk of mortality (HR = 3.22, 95% CI: 2.40-4.33).”

    Reviewpresence of cirrhosis or fibrosis

    Assessing Mortality Disparities Among Non-Alcoholic Fatty Liver Disease Metabolic Dysfunction Fatty Liver Disease and Metabolic Dysfunction-Associated Liver Disease: A Comprehensive Meta-Analysis

    Cureus

Sarcopenia

upin humans6+28% to +43%HR 1.58

6 studies
  1. Sarcopenia is associated with cirrhosis in humans (HR 1.58, 95% CI 1.39–1.79).

    “sarcopenia was associated with higher risks of incident MASLD (HR 1.37, 95% CI 1.26–1.48), cirrhosis (HR 1.58, 95% CI 1.39–1.79)”

    HumansMedian follow-up of approximately 14 yearsn = 492,305

    Muscle loss linked to higher liver disease risk in UK adults

    The journal of nutrition, health & aging

  2. Cirrhosis is linked with a higher risk of sarcopenia in humans (gastroenterology inpatients).

    “older age, female sex, presence of malnutrition, liver cirrhosis, and heart failure were independent risk factors for sarcopenia”

    Humansgastroenterology inpatientsn = 1,051

    Prevalence and Clinical Associations of Malnutrition and Sarcopenia Risk in Gastroenterology Inpatients: A Multicenter Cross-Sectional Study in Turkey

    Diagnostics (Basel, Switzerland)

  3. Cirrhosis is associated with sarcopenia in humans (cirrhosis) (42.7%).

    “The prevalence of sarcopenia was 42.7%.”

    Humanscirrhosisn = 75

    Evaluating Sarcopenia Prevalence in Cirrhotic Patients and Its Association With Child-Turcotte-Pugh and MELD (Model for End-Stage Liver Disease) Scores: A Cross-Sectional Study

    Cureus

  4. Cirrhosis is associated with sarcopenia in humans (patients with liver cirrhosis) (27.7%).

    “The prevalence of sarcopenia was 27.7%, 27.3% in male and 28.4% in female.”

    Humanspatients with liver cirrhosisn = 271

    Assessing the risk factors associated with sarcopenia in patients with liver cirrhosis: a case-control study

    Scientific reports

  5. Cirrhosis is associated with sarcopenia in humans (cirrhosis) (81.3% (314/386)).

    “Sarcopenia was detected in 314(81.3%) patients; 185(59%) males and 129(41%) females.”

    Humanscirrhosisn = 386

    Prevalence And Risk Factors Of Sarcopenia In Patients With Cirrhosis: An Observational Study

    JPMA. The Journal of the Pakistan Medical Association

  6. Sarcopenia raises the risk of cirrhosis in patients with nonalcoholic fatty liver disease (NAFLD).

    “Sarcopenia increases the risk of nonalcoholic steatohepatitis (NASH) and cirrhosis in patients with nonalcoholic fatty liver disease (NAFLD).”

    Reviewin patients with nonalcoholic fatty liver disease (NAFLD)

    Sarcopenia as a Risk Factor for Mortality in NAFLD: How Should We Diagnose It?

    Journal of digestive diseases

More on Sarcopenia

Frailty

upin humans5HR 1.9

5 studies
  1. Frailty is linked with a higher risk of cirrhosis in humans.

    “Similar results were also observed for cirrhosis, liver cancer, and liver-related mortality.”

    Humans11.6 yearsn = 339,298

    Frailty and risk of metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases

    Journal of hepatology

  2. Frailty is linked with a higher risk of cirrhosis in humans (HR 1.90, 95% CI 1.66-2.18).

    “Similar associations were observed for cirrhosis, the corresponding HRs (95% CIs) for non-frailty, pre-frailty, and frailty were 1.00 (reference), 1.29 (1.20, 1.38), and 1.90 (1.66, 2.18).”

    Humansmedian follow-up of 12.0 yearsn = 398,386

    Physical frailty, genetic predisposition, and the risks of severe non-alcoholic fatty liver disease and cirrhosis: a cohort study

    Journal of cachexia, sarcopenia and muscle

  3. Cirrhosis is associated with frailty in humans (cirrhosis) (27% (95% CI: 21-33%)).

    “the overall estimated prevalence was 27% (95% CI: 21-33%; I2 = 97.7%, P < 0.001).”

    Reviewcirrhosisn = 8,406

    The prevalence and characteristics of frailty in cirrhosis patients: a meta-analysis and systematic review

    Frontiers in medicine

  4. Cirrhosis is associated with frailty in humans.

    “Cirrhosis is often combined with frailty, which has a significant impact on patient health outcomes.”

    Review

    Research progress on the correlation between cirrhosis and frailty

    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

  5. Cirrhosis is associated with frailty in patients with cirrhosis of any cause (nearly 50%).

    “frailty is identified in nearly 50% of patients who have cirrhosis of any cause”

    Reviewin patients with cirrhosis of any cause

    Frailty in metabolic syndrome, focusing on nonalcoholic fatty liver disease

    Annals of gastroenterology

Alcohol

upin humans3RR 9.35

3 studies
  1. Alcohol is linked with a higher risk of cirrhosis in humans (10-year absolute risks of 0.14%, 0.29%, 0.68%, 2.0% and 4.6%).

    “Alcohol consumption strongly affected the risk of cirrhosis”

    Humans

    Alcohol, cardiometabolic risk factors, and cirrhosis: Ten-year risk estimates from a population-based Danish cohort

    Journal of hepatology

  2. Alcohol raises the risk of cirrhosis in humans (current consumption).

    “levels of current alcohol consumption are associated with increased risks for cancers of the breast, colorectum, oesophagus, larynx, lip and oral cavities, pharynx, liver, stomach, pancreas and prostate, as well as pancreatitis, cirrhosis”

    Reviewcurrent consumption

    Health effects associated with alcohol consumption: a Burden of Proof study

    Nature health

  3. Alcohol raises the risk of cirrhosis in humans (RR 9.35 in women and 2.82 in men at 40 g/day).

    “Dose-response evidence showed steep gradients for cirrhosis (RR 9.35 in women and 2.82 in men at 40 g/day)”

    Review40 g/dayfemales

    Alcohol use: less is better. An umbrella systematic review of clinical interventions, policies, and dose-response health risks in adults

    European journal of internal medicine

More on Alcohol

GLP-1 receptor agonists

downin humans2HR 0.7–0.787

2 studies
  1. GLP-1 receptor agonists are associated with cirrhosis in humans (Patients with type 2 diabetes and chronic viral hepatitis; compared with nonusers) (HR 0.70, 95% CI 0.56-0.86; P<0.001).

    “cirrhosis (HR 0.70, 95% CI 0.56-0.86; P<0.001)”

    HumansPatients with type 2 diabetes and chronic viral hepatitis; compared with nonusersn = 9,499

    GLP-1 receptor agonists and adverse outcomes in patients with type 2 diabetes and chronic viral hepatitis

    Clinical and molecular hepatology

  2. GLP-1 receptor agonists are linked with a lower risk of cirrhosis in humans (HR 0.787 (95% CI 0.619-0.999)).

    “GLP-1 RA use was associated with lower risks of cirrhosis (HR, 0.787; 95% CI, 0.619-0.999)”

    Humanscompared with SGLT2 inhibitor users; borderline significance, not consistent across alternative propensity score modelsn = 564

    Comparative outcomes of GLP-1 receptor agonist and SGLT2 inhibitor users after liver transplantation: An emulated target trial

    Metabolism: clinical and experimental

More on GLP-1 receptor agonists

Statins

downin humans2HR 0.74

2 studies
  1. Statins are linked with a lower risk of cirrhosis in humans (steatotic liver disease (fatty liver index ≥ 30)) (SHR, 0.66; 95% CI, 0.57–0.77).

    “and liver cirrhosis (SHR, 0.66; 95% CI, 0.57–0.77).”

    Humanssteatotic liver disease (fatty liver index ≥ 30)≥ 365 cDDDmedian 9 yearsn = 125,926

    Statin use and the risk of liver-related events in older adults with steatotic liver disease

    Scientific reports

  2. Statins are linked with a lower risk of cirrhosis in humans (HR 0.74 [95% CI 0.70-0.78], p < 0.0001).

    “In adjusted models, baseline statin use was significantly associated with a reduced risk of cirrhosis over 10 years (HR 0.74 [95% confidence interval 0.70-0.78], p < 0.0001).”

    Humansin patients with chronic liver enzyme elevation primarily associated with metabolic dysfunction10 years

    Age-specific protective effects of statins against cirrhosis in patients with chronic liver enzyme elevation associated with metabolic dysfunction: a retrospective cohort study of electronic health records

    EClinicalMedicine

More on Statins

Older age

upin humans2HR 1.14

2 studies
  1. Older age is linked with a higher risk of cirrhosis in CHB patients.

    “The prevalence of cirrhosis in female CHB patients increased faster than that in male CHB patients over 50 years old.”

    Humansin CHB patients

    Female gender lost protective effect against disease progression in elderly patients with chronic hepatitis B

    Scientific reports

  2. Older age is associated with cirrhosis in humans (Chronic hepatitis C; compared with younger patients) (HR 1.14 (1.00-1.29)).

    “Risk of cirrhosis, HCC and death was significantly elevated in elderly patients”

    HumansChronic hepatitis C; compared with younger patients

    Epidemiology and outcomes of hepatitis C infection in elderly US Veterans

    Journal of viral hepatitis

Proteomics-derived sarcopenia score

upin humans1HR 2.39

1 study
  1. Proteomics-derived sarcopenia score is associated with cirrhosis in humans (Out-of-fold ProSS) (HR 2.39, 95% CI 2.15–2.65).

    “fold-specific out-of-fold ProSS values were associated with incident MASLD (HR 1.49 per 1-SD increase, 95% CI 1.38–1.61) and cirrhosis (HR 2.39, 95% CI 2.15–2.65).”

    HumansOut-of-fold ProSSn = 51,637

    Muscle loss linked to higher liver disease risk in UK adults

    The journal of nutrition, health & aging

More on Proteomics-derived sarcopenia score

TM6SF2

upin humans1

1 study
  1. TM6SF2 is associated with cirrhosis in humans (ORs: E167K homozygotes 3.02 (95% CI 2.05–4.26); compound heterozygotes 4.96 (3.03–7.62); L156P homozygotes 9.96 (2.42–27.1)).

    “Compared to non-carriers, cirrhosis risk increased stepwise to odds ratios (ORs) of 3.02”

    HumansE167K homozygotes, compound heterozygotes, and L156P homozygotes compared with non-carrierslivern = 393,742

    Effect of two TM6SF2 variants on steatotic liver disease, cirrhosis, and hepatocellular carcinoma

    JHEP reports : innovation in hepatology

More on TM6SF2

MASLD and sarcopenia-related abnormality status

upin humans1

1 study
  1. MASLD and sarcopenia-related abnormality status is associated with cirrhosis in humans (Adjusted hazard ratios of 3.93, 7.36, and 8.48, respectively).

    “adjusted hazard ratios increased from 3.93 to 7.36 then 8.48 with MASLD alone, coexisting MASLD with low MS overall and coexisting MASLD, low MS and obesity, respectively.”

    HumansMASLD alone, coexisting MASLD with low muscle strength, and coexisting MASLD with low muscle strength and obesityMedian follow-up of 13.8 yearsn = 438,748

    Muscle problems linked to higher risks with fatty liver disease

    MedComm

All 71

Trial sponsors

Funding

31 grants since 2017

National Institute of Diabetes and Digestive and Kidney Diseases$17.6MNational Cancer Institute$8.3MUS Department of Veterans Affairs

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Human studies link cirrhosis with short telomeres, genetic predisposition to accelerated liver aging, and frailty; older age is associated with higher risk in people with chronic hepatitis B. Cirrhosis is also linked with worse cognition and higher mortality after osteoporotic hip fracture. A mouse study reports that exercise reduces cirrhosis risk in aging males.

  2. Summary rewritten as its findings changed.

    As it read before

    A human study shows SAFE and FIB-4 predict cirrhosis in steatotic liver disease. Another reports lower cirrhosis risk with GLP-1 receptor agonists in liver transplant recipients with diabetes, while a review describes lower risk with antiviral therapy in HBV infection.

  3. Summary written from the findings.

Latest

Dec 2025: 17Jan 2026: 55Feb 2026: 46Mar 2026: 52Apr 2026: 10May 2026: 13Jun 2026: 16Jul 2026: 13Aug 2026: 34Sep 2026: 34Oct 2026: 43Nov 2026: 30363 papers in 12 months
bioRxiv

Model infers biological roles of unidentified molecules

In computational benchmarks, generated descriptions more closely matched reference descriptions than competing methods, without requiring the molecules behind the signals…In computational benchmarks, generated descriptions more closely matched reference descriptions than competing methods, without requiring the molecules behind the signals to be identified first.

Preprint: computational studyAI & data
The Journal of Nutrition, Health & Aging

Muscle loss linked to higher liver disease risk in UK adults

Over about 14 years, muscle loss was linked to severe liver scarring, with a relative risk measure called a hazard ratio of 1.58 versus no muscle loss.Over about 14 years, muscle loss was linked to severe liver scarring, with a relative risk measure called a hazard ratio of 1.58 versus no muscle loss.

Cohort · 492,305 peopleBiomarkers

See all 1,036 papers on cirrhosis